Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale-Reference-Cited by-同舟云学术

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Published:2021-03 Issue: Volume:233 Page:48-58
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Carnicelli Anthony P^ORCID,Hong Hwanhee^ORCID,Giugliano Robert P,Connolly Stuart J,Eikelboom John,Patel Manesh R,Wallentin Lars^ORCID,Morrow David A,Wojdyla Daniel,Hua Kaiyuan,Hohnloser Stefan H,Oldgren Jonas,Ruff Christian T,Piccini Jonathan P,Lopes Renato D,Alexander John H^ORCID,Granger Christopher B

Funder

Boehringer Ingelheim

ohnson & Johnson and Bayer

Bristol Myers Squibb and Pfizer

Daiichi Sankyo

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

2. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation;Steffel;Eur Heart J,2018

3. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS);Hindricks;Eur Heart J,2020

4. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

5. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF;Journal of the American Heart Association;2024-09-03

2. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation;Journal of the American College of Cardiology;2024-09

3. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation;Journal of the American College of Cardiology;2024-07

4. Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants”;Circulation;2024-04-16

5. Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference;Europace;2024-03-30